Subscribe to our Newsletters !!
The connection between genes and traits is one of
Our customers depend on the high performance and r
Few names in the medical history have had a profou
Alembic Pharmaceuticals Limited appoints Mr. Manis
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of The Magazine
India is likely to acquire an approved COVID-19 vaccine by the first quarter of 2021, global brokerage firm Bernstein said in a report.
“We’re optimistic that there will be an approved vaccine in the marketplace by 1Q calendar year 2021 in India,” the report stated.
While the vaccine may be available at USD 3-6 (Rs 225 to Rs 550) per dose, herd resistance could be two decades away as a result of execution challenges,” it said, including the experience in large scale adult vaccination programmes is thin.
Bernstein, in its report, said that it is hopeful that the first group of vaccines will likely be allocated into the vulnerable inhabitants healthcare workers, population above 65 years followed by key sector workers and the economically weaker section of the populace.
“We estimate volumes to be split 55:45 involving the government channel and personal economy and procurement prices to be USD 3 per dose to the government and end-consumer costs of USD 6 in the private marketplace,” it added.
Bernstein also said that Novavax’svaccine candidate has revealed higher levels of antibodies and viral neutralisation, roughly 5-6x HCS (Individual Convalescent Sera) in comparison to AZ/Oxford’s vaccine, which came close to ordinary HCS levels.
“But, both showed enough promise to progress to Stage III and trials have been underway now, ” it included.
Stating that Serum Institute of India (SII) is best placed to deliver the very first vaccine,” Bernstein said SII has partnered with both AZ/Oxford and Novavax to manufacture and commercialise their vaccines on acceptance.
SII has present capabilities in both protein sub-unit (industrial ) and viral vector (pipeline) technologies and their existing capacities may be repurposed.
“we don’t foresee manufacturing scale-up challenges. They’re also investing in additional capacities of 1 billion doses and we estimate will likely be geared up to supply 600 million doses in 2021 and 1 billion doses at 2022 from which 400-500 million ought to be accessible for India at 2021 keeping in mind their other commitments,” the firm said.
Note :Please accept our apologies for the mistake (The term carcinogens instead of antibody) that appeared in above article published on-28th August 2020 with title :India may get covid-19 antibody by mid 2021-Bernstein.We did the correction for the same.
